[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinsons-disease-and-parkinsonism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinsons-disease-and-parkinsonism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,69,95,119,140,168,197,221,242,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643048","sensing-in-sleep-deep-brain-stimulation-100643048",false,"NCT07636720","Sensing in Sleep Deep Brain Stimulation","Sensing in Sleep and Deep Brain Stimulation","Inclusion Criteria:\n\n1. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Males and females; Age 40-80\n3. Subjects with the diagnosis of idiopathic PD consistent with the United Kingdom Parkinson Disease society brain bank criteria, or documented diagnosis of Parkinson Disease who have a Deep Brain Implant, Percept RC device to subthalamic nucleus (STN) or Globus pallidus internus (GPi).\n4. Willingness to adhere to the PSG regimen and turn DBS off for one night.\n5. A score of ≥23 on the Montreal Cognitive Assessment (MoCA)\n6. Be willing to stop any sleep hypnotics such as benzodiazepines and Ambien, with a 3 day washout period.\n\nExclusion Criteria:\n\n1. History of severe cardiovascular disease, untreated obstructive sleep apnea (OSA).\n2. History of other neurological disorders affecting the central nervous system such as stroke, multiple sclerosis, tumors, amyotrophic lateral sclerosis or muscle disease such as muscular dystrophy, myopathy.\n3. History of Dementia.\n4. Report dopaminergic medication changes in the past month.","ALL","40 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Participants in this study have Parkinson's Disease and already have a device, called the Percept RC Deep Brain Stimulation device implanted. People with Parkinson's disease often have issues related to sleep such as bad quality of sleep, waking up often and sleep apnea (breathing stops and starts during sleep).\n\nFor this study, participants will be sleeping overnight in the study sleep lab for two nights. One night, Deep Brain Stimulation (DBS) device turned on and one night with the DBS off, either in this order or the reverse.",[27,28],"Parkinson's Disease and Parkinsonism","Dyssomnia",[30,31,32],"Deep Brain Stimulation","Polysomnography","Sleep Disorders","RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-09","ACTUAL",{"date":39,"type":37},"2026-02-27",{"date":41,"type":21},"2028-02-01",{"name":43,"class":44},"The University of Texas Health Science Center at San Antonio","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100511077","aim-3-particle-swarm-optimization-pigd-100511077","NCT05934747","Aim 3 Particle Swarm Optimization PIGD","Aim 3 Particle Swarm Optimization Postural Instability Gait Disorder","* Diagnosis of Parkinson's Disease\n* Bilateral DBS in STN or GP\n* At least 3 months after lead implantation\n* Montreal Cognitive Assessment (MoCA):\n\nMoCA=23+\n\nOR: If MoCA score is 23 or less, UBACC will be performed to ensure capacity to consent. If UBACC results are unclear, the MacCAT-CR will be performed. Failed or unclear MacCAT-CR results will exclude the study candidate.\n\n* Between 18-85 years of age\n* Has undergone pre-operative 7T MRI (as part of protocol #1210M22183 or standard-of-care) and post-operative CT imaging (standard of care).\n\n8.2 Exclusion Criteria:\n\n* Inability to walk in the off-med, off-stimulation condition (even with safety harness)\n* Gait impaired significantly by a condition other than PD\n* Breaks or shorts in active contacts\n* IPG battery nearing end of life (in patients with primary-cell IPGs)\n* Females who are nursing or pregnant","18 Years","85 Years",{"count":56,"type":21},30,[24],"In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP.",[27],"2026-05-06",{"date":62,"type":37},"2026-05-08",{"date":64,"type":37},"2024-03-19",{"date":66,"type":21},"2030-01-05",{"name":68,"class":44},"University of Minnesota",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":45},"100543034","personalized-rtms-protocol-based-on-functional-reserve-to-enhance-ambulatory-function-in-pd-patients-100543034","NCT06350617","Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients","Safety and Efficacy of Personalized Repetitive Transcranial Magnetic Stimulation Protocol Based on Functional Reserve to Enhance Ambulatory Function in Patients With Parkinson Disease","Inclusion Criteria:\n\n1. patients with Parkinson's disease, diagnosed by the United Kingdom (UK) Parkinson's Disease Society Brain Bank Diagnostic Criteria,\n2. Modified Hoehn and Yahr (H\\&Y) scale, stage 2\\~4,\n3. patients who can walk on flat surfaces without the need for a gait aid,\n4. aged ≥50 years old,\n5. patients willing to sign the informed consent.\n\nExclusion Criteria:\n\n1. those with contraindications to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,\n2. those with cognitive impairment, confirmed through the Montreal Cognitive Assessment (MoCA) test as follows: \\\u003C 7 points: Illiterate \\\u003C 13 points: Education duration 0.5-3 years \\\u003C 16 points: Education duration 4-6 years \\\u003C 19 points: Education duration 7-9 years \\\u003C 20 points: Education duration 10 years or more\n3. those with coexisting neurological conditions, such as spinal cord injury or Stroke,\n4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,\n5. those with severe on-off phenomena or severe dyskinesia, deemed by the investigators to render participation in the study inappropriate.\n6. those having contraindications to conduct an MRI study,\n7. those who are pregnant or lactating,\n8. patients who have refused to participate in this study.","50 Years",{"count":78,"type":21},60,[24],"The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.",[27],[83,84,85],"Parkinson's Disease","rTMS","Functional reserve","2026-04-23",{"date":88,"type":37},"2026-04-28",{"date":90,"type":37},"2024-02-20",{"date":92,"type":21},"2026-09-30",{"name":94,"class":44},"Samsung Medical Center",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":45},"100555185","blood-flow-restriction-for-optimizing-balance-in-parkinsons-disease-100555185","NCT06508801","Blood Flow Restriction for Optimizing Balance in Parkinson's Disease","Inclusion Criteria:\n\n1. Males and females between the ages 40 - 85 with a diagnosis of idiopathic Parkinson's Disease (PD) consistent with the United Kingdom PD society brain bank criteria,\n2. in Hoehn and Yahr stage 2-4,\n3. a score of ≥23 on the mini-Mental Scale Examination.\n\nExclusion Criteria:\n\n1. History of cardiovascular disease, uncontrolled hypertension (blood pressure ≥140\u002F90 mmHg), orthostatic hypotension, deep-vein thrombosis, varicose veins, or rhabdomyolysis;\n2. Ankle branchial index ≤ 0.9 or \\> 1.3.\n3. History of other neurological disorders affecting the central nervous system such as stroke, multiple sclerosis, tumors, amyotrophic lateral sclerosis or muscle disease such as muscular dystrophy, myopathy.\n4. History of uncontrolled diabetes, severe osteoporosis, or cognitive impairment.\n5. Body mass index above 40; such individuals are more likely to have poorer muscle function and more pain.\n6. Absolute contraindications to exercise as per the American College of Sports Medicine (uncontrolled arrhythmias, third-degree heart block, recent electrocardiogram (EKG) changes, unstable angina, acute myocardial infarction, or acute congestive heart failure\n7. Had surgery in the lower extremities within the past 6 months.\n8. Pre-menopausal and not on birth control\n9. Pregnant or planning to become pregnant within the course of the study\n10. Plan to have major surgery within 2 months.",{"count":20,"type":21},[24],"This study is being done to understand how reducing blood flow (BRT) during balance-challenging strengthening exercises (instability resistance training, or IRT) can help improve symptoms of Parkinson's disease.",[27],[106,107,108,109,110],"Blood flow restriction","Instability resistance training","Balance","Strength","Postural control","2026-03-26",{"date":113,"type":37},"2026-03-31",{"date":115,"type":37},"2025-01-07",{"date":117,"type":21},"2026-12",{"name":43,"class":44},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":45},"100513209","sleep-specific-dbs-therapy-in-parkinsons-disease-100513209","NCT05962489","Sleep-specific DBS Therapy in Parkinson's Disease","Inclusion criteria:\n\n* Diagnosis of idiopathic PD\n* At least 21 years old\n* Existing or planned 7T brain imaging\n* Surgery at UMN to implant DBS system in GPi or STN with directional lead(s) is planned as part of routine clinical care\n* Surgery at UMN to implant bilateral DBS system in GPi or STN with directional lead(s) is planned as part of routine clinical care (or has already occurred, as long as the initial programming session is at least 2 weeks away)\n\nExclusion criteria:\n\n* Other significant neurological disorder\n* History of dementia\n* Patients with post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment will be excluded from further study\n* Pregnant women\n* Known radiation exposure within the last year that is determined to be unsafe when compounded with the expected radiation dose from intraoperative fluoroscopy to place ECoG strip","21 Years",{"count":127,"type":21},64,[24],"Sleep-wake disturbances are a major factor associated with reduced quality of life of individuals with Parkinson's disease (PD), a progressive neurological disorder affecting millions of people in the U.S and worldwide. The brain mechanisms underlying these sleep disorders, and the effects of therapeutic interventions such as deep brain stimulation on sleep-related neuronal activity and sleep behavior, are not well understood. Results from this study will provide a better understanding of the brain circuitry involved in disordered sleep in PD and inform the development of targeted therapeutic interventions to treat sleep disorders in people with neurodegenerative disease.",[30,27,131],"Dystonia","2026-03-02",{"date":134,"type":37},"2026-03-03",{"date":136,"type":37},"2023-06-22",{"date":138,"type":21},"2027-08-01",{"name":68,"class":44},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":45},"100608676","colonoscopic-detection-of-phosphorylated-alpha-synuclein-for-parkinsons-diagnosis-100608676","NCT07204652","Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis","Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders","Syn-G","Inclusion Criteria:\n\n* Adults 40 to 99 years of age\n* Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria\n* Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases\n\nExclusion Criteria:\n\n* Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed)\n* History of colon cancer\n* Recent gastrointestinal illness or surgical procedures\n* Pregnant or planning to become pregnant before the scheduled colonoscopy\n* Significant cognitive impairment, as determined by study investigators\n* Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes","99 Years",{"count":20,"type":21},"OBSERVATIONAL","The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is:\n\nCan doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease?\n\nCurrently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.",[153,154,27,155],"PARKINSON DISEASE (Disorder)","Parkinson","Parkinson Disease",[154,83,157,158],"Parkinson disease","Parkinson Disease (Disorder)","2026-02-09",{"date":161,"type":37},"2026-02-11",{"date":163,"type":37},"2025-09-03",{"date":165,"type":21},"2029-09",{"name":167,"class":44},"CND Life Sciences",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":45},"100604759","clinical-efficacy-and-mechanism-of-tdcs-for-dysphagia-in-pd-100604759","NCT07153692","Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD","Clinical Efficacy and Mechanism of tDCS for Dysphagia in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Meet the Chinese Diagnostic Criteria for Parkinson's Disease (2016) or MDS Diagnostic Criteria for Multiple System Atrophy or Progressive Supranuclear Palsy;\n* VFSS examination indicates dysphagia;\n* Mini-Mental State Examination (MMSE) score \\>23;\n* Willing to cooperate with the study and sign the informed consent form;\n\nExclusion Criteria:\n\n* Comorbid with other diseases that cause dysphagia;\n* Comorbid with pneumonia, or severe cardiac\u002Frenal insufficiency;\n* Having metal implants in the body\n* With cognitive impairment or inability to cooperate.","100 Years",{"count":177,"type":21},58,[24],"This study aims to verify transcranial direct current stimulation(tDCS) efficacy for Parkinson's disease (PD)-related dysphagia and its mechanism. Subjects are randomly split into two groups: control (sham tDCS + conventional dysphagia treatment) and experimental (real tDCS + conventional treatment).\n\nAssessments will be conducted at baseline, after the completion of intervention, and at the 3-month follow-up. Swallowing function will be evaluated via gold-standard videofluoroscopic swallowing study (VFSS) and scales. Resting-state functional magnetic resonance imaging (rs-fMRI) or functional near-infrared spectroscopy (fNIRS) will be measures for tracking changes in abnormal brain regions\u002Fnetworks.\n\nCorrelations between swallowing recovery and brain function changes, plus group imaging differences, will reveal tDCS's neurophysiological mechanism.",[27,181],"Dysphagia",[183,184,185,186,187],"Parkinson's disease","Atypical Parkinsonian Syndromes","dysphagia","tDCS","VFSS","2025-08-30",{"date":190,"type":37},"2025-09-04",{"date":192,"type":37},"2025-07-17",{"date":194,"type":21},"2030-03-31",{"name":196,"class":44},"Wang Ping",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100546826","mechanism-and-application-of-dbs-in-the-treatment-of-pd-100546826","NCT06400017","Mechanism and Application of DBS in the Treatment of PD","Mechanism and Application of Deep Brain Stimulation in the Treatment of Parkinson's Disease","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study and sign the informed consent;\n* Age 50-70 years old, gender unlimited;\n* The clinical diagnosis is consistent with typical PD, and the medical history is less than 20 years;\n* Patients who intend to use 3.0T magnetic resonance compatible dual-channel DBS device (G106R or G106RS, Beijing Pinchi Company) for bilateral subthalamic nucleus DBS surgery to control PD symptoms;\n* MRI excluded patients with obvious structural changes;\n* The visual acuity and hearing of the subjects were basically normal, and the compliance was good, and they could complete the tasks listed in the experimental scheme in accordance with the standards.\n\nExclusion Criteria:\n\n* Serious mental, cognitive and psychological disorders, unable to sign informed consent or cooperate with the operation and various tasks;\n* There are contraindications for neurosurgery, such as hydrocephalus, cerebral atrophy, cerebrovascular sequelae, heart disease and other cardiovascular and cerebrovascular diseases;\n* There are concomitant diseases that seriously affect health, such as tumors, serious abnormalities of liver and kidney function (indexes more than 3 times normal);\n* There is intracranial space occupation, cerebrovascular disease, mental illness, other neurological diseases, claustrophobia, or there is an implant in the body, which affects the nuclear magnetic scan;\n* The results of the Mini-Mental State Scale (MMSE) \\\u003C24 or the Montreal Cognitive Assessment Scale (MoCA) \\\u003C18 in the preoperative assessment, or the results of other scales indicate the presence of severe dementia.","70 Years",{"count":78,"type":21},[24],"Project name: The mechanism and application of deep brain stimulation in the treatment of Parkinson's disease\n\nObjective:\n\nTo test the hypothesis that electrical stimulation of substantia nigra regulates cognitive dysfunction in Parkinson's disease and to reveal its electrophysiological mechanism.\n\nStudy design:\n\nThis study is a self-controlled prospective cohort study. By comparing the behavioral characteristics of the memory paradigm under microelectrode stimulation during DBS operation and the characteristics of the underlying electrophysiological signals, and the behavioral characteristics of the memory paradigm and the characteristics of brain network activity under electrical stimulation when DBS is turned on 1 month after surgery. The regulatory effect of substantia nigra DBS on memory network was analyzed.\n\nCases: 60\n\nCase selection:\n\nInclusion criteria:\n\n1)Voluntarily participate in the clinical study and sign the informed consent; 2) Age 50-70 years old, gender unlimited; 3) The clinical diagnosis is consistent with typical PD, and the medical history is less than 20 years; 4) Patients who intend to use 3.0T magnetic resonance compatible dual-channel DBS device (G106R or G106RS, Beijing Pinchi Company) for bilateral subthalamic nucleus DBS surgery to control PD symptoms; 5) MRI excluded patients with obvious structural changes; 6) The visual acuity and hearing of the subjects were basically normal, and the compliance was good, and they could complete the tasks listed in the experimental scheme in accordance with the standards.\n\nExclusion criteria:\n\n1)Serious mental, cognitive and psychological disorders, unable to sign informed consent or cooperate with the operation and various tasks; 2) There are contraindications for neurosurgery, such as hydrocephalus, cerebral atrophy, cerebrovascular sequelae, heart disease and other cardiovascular and cerebrovascular diseases; 3) There are concomitant diseases that seriously affect health, such as tumors, serious abnormalities of liver and kidney function (indexes more than 3 times normal); 4) There is intracranial space occupation, cerebrovascular disease, mental illness, other neurological diseases, claustrophobia, or there is an implant in the body, which affects the nuclear magnetic scan; 5) The results of the Mini-Mental State Scale (MMSE) \\\u003C24 or the Montreal Cognitive Assessment Scale (MoCA) \\\u003C18 in the preoperative assessment, or the results of other scales indicate the presence of severe dementia.\n\ntherapeutic schedule： This study did not change the patient's overall treatment regimen, and only electrical stimulation was tested during and after DBS surgery\n\nEfficacy evaluation:\n\nEffectiveness evaluation index (primary efficacy index and secondary efficacy index) : accuracy of memory paradigm, response speed Safety evaluation indicators: blood pressure, heart rate, dual frequency index, patient complaints and symptoms\n\nStatistical methods:\n\nThe group t test was used to compare the normal distribution between the measurement data groups. For measurement data with non-normal distribution, Wilcoxon rank sum test was used for comparison between groups.\n\nThe study period is January 1, 2024 - December 31, 2026.",[27],[210,211],"Cognitive dysfunction","Electrical stimulation of substantia nigra","2025-05-27",{"date":214,"type":37},"2025-05-31",{"date":216,"type":37},"2024-07-01",{"date":218,"type":21},"2026-12-31",{"name":220,"class":44},"Beijing Tiantan Hospital",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":18,"enrollmentInfo":229,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":45},"100586368","neural-mechanisms-and-clinical-applications-of-dbs-for-modulating-sleep-dysregulation-in-pd-100586368","NCT06914466","Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD","Neural Mechanisms and Clinical Applications of Deep Brain Stimulation for Modulating Sleep Dysregulation in Parkinson's Disease","Inclusion Criteria:\n\n1. Diagnosis of Parkinson's disease: The diagnostic criteria for Parkinson's disease are the Clinical Diagnostic Criteria of UK PD Society Brain Bank Clinical Diagnostic Criteria or 2015 MDS Clinical Diagnostic Criteria for PD.All diagnoses of Parkinson's disease were made by three neurologists who were experienced in the field of movement disorders.\n2. Patients who underwent bilateral STN-DBS(Medtronic Percept™ PC)\n3. Patients who can cooperate with the completion of postoperative follow-up and clinical evaluation.\n\nExclusion Criteria:\n\n1. Patients who underwent other brain surgery;\n2. Other patients with secondary Parkinson's syndrome and Parkinsonism-plus syndrome;\n3. Patients with other central nervous system and peripheral nervous system diseases;\n4. Patients complicated with severe medical system diseases, or unable to tolerate clinical evaluation;\n5. Patients with severe mental illness;\n6. Patients who cannot complete informed consent due to cognitive and communication barriers, or refuse to sign informed consent.","19 Years",{"count":20,"type":21},"Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by both motor and non-motor symptoms. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectively alleviates motor symptoms; however, non-motor symptoms such as sleep disorders significantly impair patients' quality of life. While preliminary evidence suggests DBS may improve sleep, the underlying neural mechanisms and long-term effects on sleep regulation remain poorly elucidated. This study employs a wearable polysomnography (PSG) device to investigate how STN-DBS modulates sleep architecture, local field potentials (LFPs), and clinical outcomes in PD patients. We hypothesize that STN-DBS contributes to both the regulation and disruption of normal sleep behavior. By synchronizing PSG with STN-LFP recordings under DBS-ON and DBS-OFF conditions, we aim to decode sleep stages using STN-LFPs, characterize PD-specific sleep abnormalities (e.g., sleep architecture, atonia), and analyze DBS-induced LFP changes and their correlations with clinical efficacy. According to the above data, the sleep stage characteristics were decoded, and the algorithm was used to determine the optimal clinical threshold current amplitude to improve sleep. Then, the patients will be given adaptive stimulation, and the sleep quality was monitored to verify its efficacy.This study will provide a neurophysiological foundation for developing closed-loop stimulation strategies targeting sleep dysfunction in PD.",[30,27,232],"Sleep Disorder","2025-03-30",{"date":235,"type":37},"2025-04-06",{"date":237,"type":37},"2024-09-01",{"date":239,"type":21},"2026-12-01",{"name":241,"class":44},"Xuanwu Hospital, Beijing",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":251,"conditions":252,"keywords":280,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":45},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":250,"type":21},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[253,254,255,256,257,258,259,260,261,262,263,264,265,155,27,266,267,268,269,270,271,272,273,274,275,276,277,278,279],"ALS","Amyotrophic Lateral Sclerosis","Alzheimer Disease","Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Corticobasal Degeneration","Dementia","Frontotemporal Dementia","Huntington Disease","Lewy Body Disease","Multiple Sclerosis","Multiple System Atrophy","Progressive Supranuclear Palsy","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[253,254,255,258,259,260,261,262,263,264,265,155,281,266,267,268,282,283,272,284,273,274,275,276,277,278,279],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":287,"type":37},"2025-03-03",{"date":289,"type":37},"2022-11-10",{"date":291,"type":21},"2045-11-10",{"name":293,"class":44},"New York Stem Cell Foundation Research Institute",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":45},"100529528","the-use-of-the-cue1cue1-in-people-with-parkinsons-disease-and-related-disorders-100529528","NCT06174948","The Use of the CUE1\u002FCUE1+ in People With Parkinson's Disease and Related Disorders","The Use of the CUE1\u002FCUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adults over 18 years old\n* Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as atypical dystonias and tremor disorders and Orthostatic Tremor (OT)\n* willing to participate and written consent provided after read the participant information sheet.\n\nExclusion Criteria:\n\nIndividuals with:\n\n* other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait\n* metabolic or autoimmune disorders affecting movement, balance and gait\n* acute orthopaedic disorders influencing balance control and gait\n* audiovestibular disorders including severe hearing loss\n* visual disturbances, poor eyesight\n* not able to provide written consent form to participate\n* clinical diagnosis of cognitive impairment including dementia or Alzheimer's.\n* Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported)\n\nTechnical contraindications related to CUE1 device:\n\n* implanted metallic or electronic devices usage\n* hypersensitivity to vibrotactile stimulation\n* skin conditions and\u002For open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.",{"count":302,"type":21},70,[24],"People with Parkinson's disease (PD) commonly experience a range of both motor (e.g., bradykinesia, rigidity, tremor, and postural instability) and non-motor (e.g., fatigue, psychiatric and behavioural disturbances, autonomic dysfunction, cognitive impairment, sleep dysfunction and olfactory loss) features. Currently, it is challenging to alleviate these symptoms with first-line treatment, the medications such as levodopa. The CUE1 is a non-invasive device, which is approved for sale in the UK market as a Class I low risk device. It is worn on the sternum or other part of the body such as the forearm and attaches to the skin via an adhesive patch which has been dermatologically tested and approved.\n\nThe CUE1 delivers pulsing cueing and vibrotactile stimulation to help improve symptoms in people with PD and it has shown to be effective in doing so in previous small case studies. This 9-week feasibility study aims to investigate the feasibility, safety, tolerability and effect of using the CUE1 as an intervention to improve motor and non-motor symptoms in people with PD and related movement disorders. People with clinical diagnosis of idiopathic PD and related disorders including those with progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, orthostatic tremor and vascular Parkinsonism as well as atypical dystonias and tremor disorders aged over 18 years old who have the capacity to provide a written consent form to take part in the study, will receive as intervention to wear the CUE1 device at home, on daily basis while carrying out their activities of daily living. Participants will also have to attend face-to-face appointments of approximately half a day, to discuss how they are getting on with using the CUE1 and complete questionnaires on their symptoms, walking, balance, and movement tests as well as a participant's clinical diary.",[27,266,306,131,265,259,307,308],"Different Types of Tremor Including Essential Tremor","Vascular Parkinsonism","Orthostatic Tremor",[310],"CUE1, Parkinson's disease, movement disorders","2024-11-18",{"date":313,"type":37},"2024-11-21",{"date":315,"type":37},"2024-03-25",{"date":317,"type":21},"2025-03-31",{"name":319,"class":44},"Queen Mary University of London"]